Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

BioPharma DiveKardigan extends biotech’s streak of big IPOs with $400M haul

Endpoints NewsKardigan raises $400M in IPO to back three clinical-stage cardio drugs

Endpoints NewsBiogen makes up to $1B deal for secretive anti-inflammatory biotech

FierceBiotech‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC game

SchunkHealthy and thriving: ARPM, MAPP companies maintain safety as top priority - Rubber News

Clinical OMICsHave Microbubbles Burst Through the Barriers of Genetic Medicine Delivery?

AgilentAgilent (A) Has a Consumables-and-Service Analytical Platform Bigger Than a Biotech-Funding Proxy - AlphaStreet

Clinical OMICsOLE Identified as a Potential Alzheimer’s Therapy Targeting Microglia

Endpoints NewsFDA gives rejected drugs another chance in post-Makary era

10x Genomics Blog10x Genomics (TXG) Launches Cleveland Clinic Partnership For Bladder Cancer Diagnostics - simplywall.st

Clinical OMICsAI Discovers Two New Antibiotics for Drug-Resistant Gonorrhea